Prevention of late breast cancer (BC) events in postmenopausal women with endocrine responsive BC.

预防患有内分泌反应性 BC 的绝经后妇女的晚期乳腺癌 (BC) 事件。

• 批准号: nhmrc : 510787
• 负责人: Prof Alan Coates
• 金额: $ 312.57万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/prevention-late-breast-responsive-bc/98930
• 关键词: Prevention; late; breast; cancer; BC

This proposal is from Australia's national breast cancer (BC) trials group, the ANZ BCTG, for a new phase III, multi-centre clinical trial evaluating whether much later endocrine therapy with an aromatase inhibitor can prevent BC recurrence in postmenopausal women who have: had hormone sensitive BC at least 6 years ago; were treated by Tamoxifen more than 1 year ago; and, are currently disease free. Subjects will randomly receive letrozole or placebo as a daily tablet for five years.

这项建议来自澳大利亚国家乳腺癌(BC)试验小组ANZ BCTG，这是一项新的III期多中心临床试验，评估很久以后使用芳香酶抑制剂进行内分泌治疗是否可以防止患有激素敏感型BC的绝经后女性的BC复发：至少6年前患有激素敏感型BC；1年多前接受他莫昔芬治疗；以及目前无病。受试者将随机接受来曲唑或安慰剂作为每日片剂，为期五年。